Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (7): 695-698.DOI: 10.3969/j.issn.1673-8640.2022.07.019
Previous Articles Next Articles
Received:2021-04-21
Revised:2022-02-27
Online:2022-07-30
Published:2022-08-26
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.07.019
| 组别 | 例数 | 年龄/ 岁 | 性别 | 高血压史/ [例（%）] | 糖尿病史/[例（%）] | 总胆固醇/（mmol/L） | 三酰甘油/（mmol/L） | |||
|---|---|---|---|---|---|---|---|---|---|---|
| 男/例 | 女/例 | |||||||||
| Ⅰ组 | 35 | 60.35±14.71 | 17 | 18 | 17（48.50） | 5（14.28） | 4.33±1.52 | 1.49±0.66 | ||
| Ⅱ组 | 33 | 66.12±13.66 | 19 | 14 | 24（72.72） | 8（24.24） | 4.02±1.20 | 1.17±0.40 | ||
| Ⅲ组 | 31 | 66.94±13.17 | 16 | 15 | 26（83.87） | 11（35.48） | 4.11±1.54 | 1.20±0.56 | ||
| Ⅳ组 | 34 | 63.79±14.95 | 16 | 18 | 27（79.41） | 15（44.12） | 4.48±1.29 | 1.37±0.67 | ||
| 统计值 | 1.46 | 0.751 | 10.11 | 8.32 | 0.74 | 2.16 | ||||
| P值 | 0.23 | 0.86 | 0.02 | 0.04 | 0.53 | 0.10 | ||||
| 组别 | PTH/ （pg/mL） | NT-proBNP/ （ng/L） | 钙/ （mmol/L） | 磷/ （mmol/L） | LVEF/ % | 左心室肥厚/[例（%）] | eGFR/[mL/（min·1.73 m2）] | |||
| Ⅰ组 | 56.34 （28.56,96.71） | 214.05 （112.50,453.70） | 2.15±0.26 | 1.14±0.32 | 60±6.88 | 6（17.14） | 60.61±41.37 | |||
| Ⅱ组 | 203.2 （123.80,292.50） | 2 823 （1 632,4 253） | 2.05±0.22 | 1.47±0.43* | 59.52±9.68 | 19（57.57） | 19.80±10.09* | |||
| Ⅲ组 | 244.6 （156.89,335.13） | 10 252 （5 407,27 353） | 1.89±0.20*# | 1.61±0.47* | 53.64±9.19* | 21（67.74） | 11.11±5.22*# | |||
| Ⅳ组 | 293.3 （139.4,468） | 15 223 （5 642,35 000） | 1.94±0.26* | 1.65±0.44* | 54.06±8.31* | 23（67.65） | 9.33±4.58*# | |||
| 统计值 | 39.60 | 89.74 | 7.96 | 10.21 | 5.307 | 22.41 | 41.01 | |||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.002 | <0.001 | <0.001 | |||
| 组别 | 例数 | 年龄/ 岁 | 性别 | 高血压史/ [例（%）] | 糖尿病史/[例（%）] | 总胆固醇/（mmol/L） | 三酰甘油/（mmol/L） | |||
|---|---|---|---|---|---|---|---|---|---|---|
| 男/例 | 女/例 | |||||||||
| Ⅰ组 | 35 | 60.35±14.71 | 17 | 18 | 17（48.50） | 5（14.28） | 4.33±1.52 | 1.49±0.66 | ||
| Ⅱ组 | 33 | 66.12±13.66 | 19 | 14 | 24（72.72） | 8（24.24） | 4.02±1.20 | 1.17±0.40 | ||
| Ⅲ组 | 31 | 66.94±13.17 | 16 | 15 | 26（83.87） | 11（35.48） | 4.11±1.54 | 1.20±0.56 | ||
| Ⅳ组 | 34 | 63.79±14.95 | 16 | 18 | 27（79.41） | 15（44.12） | 4.48±1.29 | 1.37±0.67 | ||
| 统计值 | 1.46 | 0.751 | 10.11 | 8.32 | 0.74 | 2.16 | ||||
| P值 | 0.23 | 0.86 | 0.02 | 0.04 | 0.53 | 0.10 | ||||
| 组别 | PTH/ （pg/mL） | NT-proBNP/ （ng/L） | 钙/ （mmol/L） | 磷/ （mmol/L） | LVEF/ % | 左心室肥厚/[例（%）] | eGFR/[mL/（min·1.73 m2）] | |||
| Ⅰ组 | 56.34 （28.56,96.71） | 214.05 （112.50,453.70） | 2.15±0.26 | 1.14±0.32 | 60±6.88 | 6（17.14） | 60.61±41.37 | |||
| Ⅱ组 | 203.2 （123.80,292.50） | 2 823 （1 632,4 253） | 2.05±0.22 | 1.47±0.43* | 59.52±9.68 | 19（57.57） | 19.80±10.09* | |||
| Ⅲ组 | 244.6 （156.89,335.13） | 10 252 （5 407,27 353） | 1.89±0.20*# | 1.61±0.47* | 53.64±9.19* | 21（67.74） | 11.11±5.22*# | |||
| Ⅳ组 | 293.3 （139.4,468） | 15 223 （5 642,35 000） | 1.94±0.26* | 1.65±0.44* | 54.06±8.31* | 23（67.65） | 9.33±4.58*# | |||
| 统计值 | 39.60 | 89.74 | 7.96 | 10.21 | 5.307 | 22.41 | 41.01 | |||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.002 | <0.001 | <0.001 | |||
| [1] |
BANSAL N, ZELNICK L R, BALLANTYNE C M, et al. Upper reference limits for high-sensitivity cardiac troponin T and N-terminal fragment of the prohormone brain natriuretic peptide in patients with CKD[J]. Am J Kidney Dis, 2022, 79(3):383-392.
DOI URL |
| [2] |
BJURMAN C, PETZOLD M, VENGE P, et al. High-sensitive cardiac troponin,NT-proBNP,hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease[J]. Clin Biochem, 2015, 48(4-5):302-307.
DOI URL |
| [3] | 张杰良, 黄雪珍, 邓文成, 等. 合并不同心血管疾病肾功能不全患者NT-proBNP与hs-TnT的临床检测[J]. 实用检验医师杂志, 2020, 12(3):143-146. |
| [4] | National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification[J]. Am J Kidney Dis, 2002, 39(2 Suppl 1):S1-S266. |
| [5] | 杨硕, 怀伟, 刘桂花, 等. 高敏心肌肌钙蛋白T在急性心肌梗死早期诊断中的临床价值[J]. 中华检验医学杂志, 2014, 37(2):150-154. |
| [6] |
LEVEY A S, BOSCH J P, LEWIS J B, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine:a new prediction equation. Modification of Diet in Renal Disease Study Group[J]. Ann Intern Med, 1999, 130(6):461-470.
DOI URL |
| [7] |
CANNEY M, TANG M, ER L, et al. Glomerular filtration rate-specific cutoffs can refine the prognostic value of circulating cardiac biomarkers in advanced chronic kidney disease[J]. Can J Cardiol, 2019, 35(9):1106-1113.
DOI URL |
| [8] | LIM E, LEE M J. Optimal cut-off value of high-sensitivity troponin I in diagnosing myocardial infarction in patients with end-stage renal disease[J]. Medicine(Baltimore), 2020, 99(5):e18580. |
| [9] |
CHESNAYE N C, SZUMMER K, BÁRÁNY P, et al. Association between renal function and troponin t over time in stable chronic kidney disease patients[J]. J Am Heart Assoc, 2019, 8(21):e013091.
DOI URL |
| [10] |
HSU C K, WU I W, CHEN Y T, et al. Value of the high-sensitivity troponin T assay for diagnosis of acute myocardial infarction in patients with and without renal insufficiency[J]. Ren Fail, 2020, 42(1):1142-1151.
DOI URL |
| [11] |
KRAUS D, VON JEINSEN B, TZIKAS S, et al. Cardiac troponins for the diagnosis of acute myocardial infarction in chronic kidney disease[J]. J Am Heart Assoc, 2018, 7(19):e008032.
DOI URL |
| [12] |
BANSAL N, ZELNICK L, SHLIPAK M G, et al. Cardiac and stress biomarkers and chronic kidney disease progression:the CRIC study[J]. Clin Chem, 2019, 65(11):1448-1457.
DOI URL |
| [13] | 王佳旺, 曹绪芬, 徐泽升. 非心源性心肌酶升高3例[J]. 国际心血管病杂志, 2019, 46(4):254-255. |
| [14] |
LIEM V G B, HOEKS S E, GRÜNE F, et al. Prognostic value of postoperative high-sensitivity troponin T in patients with different stages of kidney disease undergoing noncardiac surgery[J]. Br J Anaesth, 2018, 120(1):84-93.
DOI URL |
| [15] |
WANG J, QIU X, XU T, et al. Sclerostin/receptor related protein 4 and ginkgo biloba extract alleviates β-glycerophosphate-induced vascular smooth muscle cell calcification by inhibiting Wnt/β-catenin pathway[J]. Blood Purif, 2019, 47 (Suppl 1):17-23. =LYNGBAKKEN M N,AAGAARD E N,KVISVIK B,et al. Cardiac troponin I and T are associated with left ventricular function and structure:data from the Akershus Cardiac Examination 1950 Study[J]. Clin Chem,2020,66(4):567-578.
DOI URL |
| [16] | 杨峻, 宦红娣, 张军力, 等. 血清成纤维细胞生长因子23在慢性肾功能衰竭中的相关性研究[J]. 检验医学, 2009, 24(10):711-714. |
| [17] |
ODUM E P, YOUNG E E. Elevated cardiac troponin I,creatine kinase and myoglobin and their relationship with cardiovascular risk factors in patients with type 2 diabetes[J]. Diabetes Metab Syndr, 2018, 12(2):141-145.
DOI URL |
| [18] |
JANUS S E, HAJJARI J, AL-KINDI S. High-sensitivity troponin and the risk of atrial fibrillation in chronic kidney disease:results from the chronic renal insufficiency cohort study[J]. Heart Rhythm, 2020, 17(2):190-194.
DOI URL |
| [19] |
SANDESARA P B, O'NEAL W T, TAHHAN A S, et al. Comparison of the association between high-sensitivity troponin I and adverse cardiovascular outcomes in patients with versus without chronic kidney disease[J]. Am J Cardiol, 2018, 121(12):1461-1466.
DOI URL |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
